-
American Nobel laureate in medicine hopes to illuminate the brain
-
Tens of thousands expected in Paris for high school protests
-
Trump approves firing squad for convicted US military base shooter
-
AI borrowing binge rattles US markets
-
Grappling with 'homework scams,' US universities shun AI detectors
-
Young Canadians sue government over alleged climate failures
-
Separatists win Quebec election in test for Canada PM
-
White Sox down Guardians to take 2-0 series lead
-
Leaders visit Pacific atoll at frontline of climate change
-
NHL record-breaker Ovechkin says current season will be his last
-
Yemen's Houthis claim striking Riyadh airport, other Saudi sites
-
France roar back in Nations League as Italy beat Turkey
-
Best-selling British author Jeffrey Archer dies aged 86
-
Messi readies for final farewell in Argentina send-off
-
Military plane crash kills 32 in Nigeria
-
Esposito seals Italy win over Turkey in Nations League
-
Olise powers France to win over Belgium in Nations League
-
Russia downplays plague reports as Trump offers US help
-
High-flying Blazy turns to birdlife at Chanel
-
Trump says US moved bombers from UK base after 'threats'
-
Riyadh's allies pledge troops as Yemen, Saudi Arabia attack Houthis
-
Brazilian stocks surge to record after Bolsonaro election lead
-
Clashes erupt outside Kosovo parliament over war crimes court
-
Leaders to visit Pacific atoll at frontline of climate change
-
Milan's Saelemaekers suffers ankle setback, faces lengthy spell out
-
ICC gives more details about arrest warrants for Taliban ministers
-
Rubio arrives in Iceland to push for greater US presence in Arctic
-
Nigeria's Tinubu confirms 32 dead after military plane crash
-
Putin allows Italy's UniCredit to sell part of Russian business
-
'Reckless' AI firms can't control models, says whistleblower
-
Djokovic into China Open final as Medvedev out for hitting fan with ball
-
Switching on brain cells: the Nobel-winning science of optogenetics
-
ICC unseals arrest warrants for Taliban education ministers
-
Quebec votes as separatist surge poses test for Canada PM
-
Modric hopes fans back Croatia against Spain after England shame
-
Euro slides as concerns about French debt mount
-
Bolsonaro rides right-wing surge into Brazil's election runoff
-
Former Trump press secretary Leavitt joins Fox News
-
Turkey blocks X account of British reporter
-
Djokovic advances to China Open final as Medvedev out for hitting fan with ball
-
Ukraine says using AI robot guns to shoot down new Russian drones
-
Disgraced former US House speaker dies at 84
-
At Oct 7 memorial, Netanyahu says will be no Hamas rule in Gaza
-
Euro slides as worries about French debt grow
-
Ukraine blames Russia for deadly sinking of Turkish ship in Black Sea
-
US withdraws all bomber aircraft from UK airbase
-
UN rights council slams Taliban's 'oppression' of women
-
Drone hits Ethiopia IDP camp as fears grow of regional war
-
Norway eyes partial ban of smart glasses
-
US-German trio wins medicine Nobel for illuminating the brain
Medical Care Technologies Inc. (OTCID:MDCE) Reports First-Pass Results From Volunteer Image Evaluation Inside Melanoma Scan Beta
Initial Review Shows Real-World User Photos Can Move Through Quality Scoring, Body-Map Registration and Change-Over-Time Comparison
MESA, AZ / ACCESS Newswire / September 29, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reported first-pass results from internal evaluation of its initial volunteer-submitted image datasets for MDCE Melanoma Scan Beta.

The update follows the September 16 announcement that the first human volunteer datasets had been received and the September 23 announcement that internal review had begun. Those releases established collection and the start of analysis. This release reports what the first evaluation pass showed.
Until the volunteer phase, development relied on public dermatology archives, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The first volunteer set introduced uncontrolled capture conditions. First-pass review was designed to answer a practical question: can those real-world photographs move through the beta workflow?
First-pass findings
Image-quality scoring
A substantial portion of the initial volunteer images met internal usability thresholds for focus, framing, and visible-area isolation. Images that did not meet those thresholds were held out of mapping and comparison. That split is itself a result: the workflow can separate usable samples from captures that are too distant, poorly lit, or too compressed for a comparison pass.
Body-map registration
Usable images were successfully assigned to mapped body regions inside the beta architecture. First-pass review indicated that volunteer photographs can be placed on the interactive body map with enough locational consistency to support later retrieval of the same site.
Longitudinal comparison
Where more than one usable image could be associated with the same mapped area, the platform completed side-by-side visual review. First-pass testing confirmed that successive user-captured images can be organized for change-over-time comparison. This finding concerns workflow function. It is not a medical result.
These first-pass outcomes do not constitute clinical validation, performance benchmarks, or diagnostic accuracy claims. They indicate that volunteer-submitted photographs can enter the system, be quality-filtered, be mapped, and - when a second image exists - be compared.
MDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and body-map monitoring application intended to help users catalog visible skin images and review the same mapped area across sessions. The platform remains in beta-stage development. It has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It is not a substitute for professional medical advice, screening, or evaluation by a qualified healthcare provider.
"The first pass did what we needed it to do," said Marshall Perkins, CEO of Medical Care Technologies. "Real-world photos made it through quality scoring. They registered to the body map. Where we had more than one image of the same site, comparison ran. That is forward progress from collecting data to seeing the workflow function on volunteer input."
Volunteer participation is not a clinical diagnosis program. Any concern about a skin change should be reviewed by a licensed clinician. Medical Care Technologies will continue its multi-phase testing protocol and additional evaluation passes as more volunteer-submitted images are collected.
Investors and interested parties can learn more at:
https://www.medicalcaretechnologies.com
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID: MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: [email protected]
Website: https://www.medicalcaretechnologies.com
SOURCE: Medical Care Technologies Inc.
View the original press release on ACCESS Newswire
F.Ramirez--AT